Celea Therapeutics’ $180M financing will support a Phase 3 IPF drug trial comparing deupirfenidone with Esbriet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results